Outpatient Surgery Magazine

Pushing For Change - July 2020 - Subscribe to Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/1268525

Contents of this Issue

Navigation

Page 86 of 110

©2020 NeoTract, Inc. All rights reserved. MAC00901-05 Rev B I am a urologist. I am a patient. Enlarged Prostate (BPH) affects over 40 million men in the United States. Symptoms may include interrupted sleep and urinary problems as well as loss of productivity, depression and decreased quality of life. 2 Learn more and check out the data at UroLift.com/info If your patients have symptoms of an enlarged prostate, introduce them to the UroLift ® System. Here's why I chose UroLift System and recommend it to my patients. Proven, minimally invasive approach to treating enlarged prostate that provides rapid symptom relief and recovery 3,4 An earlier alternative to medical therapy that provides symptom relief better than reported for medication 3,5 Durability through 5 years 6 Over 175,000 ** men have been treated with the UroLift System worldwide The procedure is covered by Medicare and all major private insurers when medical criteria are met. wide when PRE-PROCEDURE POST-PROCEDURE " " When my BPH symptoms became unbearable I really didn't want to undergo invasive surgery and I'm not a personal fan of BPH medications. Relief can be inadequate and temporary and they have a whole host of side effects. 1 Peter J. Walter, M.D., F.A.C.S. * Western New York Urology Associates and UROLIFT ® SYSTEM PATIENT UroLift ® Implant Actual Size The UroLift System procedure is FDA-cleared for the treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral and median lobe hyperplasia, in men 45 years of age or older. Results and patient experience may vary. Clinical data from a pivotal 206-patient randomized controlled study showed that most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within 2 to 4 weeks after the procedure. *Dr. Walter is UroLift System faculty and a paid consultant for NeoTract|Teleflex **Management estimate based on product sales and average units per procedure. 1. AUA Guidelines 2003, 2010; 2. Speakman et al. 2014 BJUI International; 3. Roehrborn J Urol 2013 L.I.F.T. Study; 4: Shore, Can J Urol 2014 Local Study; 5. AUA BPH Guidelines 2003; 6. Roehrborn et al. Can J Urol 2017

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Pushing For Change - July 2020 - Subscribe to Outpatient Surgery Magazine